



The evidence demonstrated that 3M™ V.A.C.® Therapy was substantially more cost-effective than competitor negative pressure wound therapy.


Once again, results from a retrospective analysis of insurance claims for 15,180 patients who received NPWT in the outpatient setting show that*:



V.A.C.® Therapy patients had lower total and wound-related costs across all time periods




Costs at 30 days, 3 months, 12 months: All wounds



V.A.C.® Therapy patients had lower total and wound-related costs across all wound types at 12 months



Costs at 12 months: Key wound types




V.A.C.® Therapy patients experienced shorter average length of therapy



How can V.A.C.® Therapy give you the opportunity to treat more patients?

Percentage of patients who remained on NPWT



Learn more about leading NPWT solutions from 3M.

Visit our NPWT page now!

The data shows V.A.C.® Therapy was substantially more cost-effective at 30 days, three months, and 12 months when evaluating total and wound-related costs for acute and chronic wound patients treated with negative pressure wound therapy.

The study retroactively evaluated a national insurance claims database to assess costs, treatment duration, and multiple sites of care for V.A.C.® Therapy and other systems.

Reference: *Law_2020_Cureus (v0.1) A L, Krebs B, Karnik B, et al. (November 30, 2020) Comparison of Healthcare Costs Associated With Patients Receiving Traditional Negative Pressure Wound Therapies in the Post-Acute Setting. Cureus 12(11): e11790.

Note: Specific indications, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product Instructions for Use prior to application. Rx only.